RRRahul Raghavan

Rahul Raghavan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rahul Raghavan has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Structure-guided Active Site Affinity Ligand Unmasks a Stress-Sensitizing Role for BLVRB in the Endoplasmic Reticulum

    by Rahul Raghavan Thekke Veedu, Jawaad Sheriff, Natasha M. Nesbitt, Natalia Marchenko, Lisa Pennacchia, Tiziana Ginex, Patrick Hearing, Dale F. Kreitler, Wadie F. Bahou

    Biliverdin IXb reductase (BLVRB) is an NAD(P)H-dependent oxidoreductase that regulates hematopoiesis and cellular stress, although measurement and sequelae of cellular active site engagement remain undefined. Here, we report the development of a nanoBRET platform enabling real-time BLVRB target engagement. Structure-guided design and chemical syntheses of BODIPY-labeled pyrazolopyrimidinone inhibitors generate cell-permeable acceptor ligands retaining high-affinity binding to the BLVRB active site. In vitro and cellular nanoBRET assays demonstrate specific energy transfer and inform equilibrium binding affinities, target engagement, and residence time analyses for diverse panels of BLVRB inhibitors. NanoBRET demonstrates strong concordance with enzymatic inhibition and is validated by crystallographic structures confirming active site binding. Live-cell imaging using affinity ligands reveals predominant endoplasmic reticulum localization and transient suppression of the ER stress chaperone GRP78/BiP without eliciting a canonical unfolded protein response. These studies inform a redox-regulated mechanism whereby spatiotemporal BLVRB active site engagement functions as a stress sensitizer modulating ER proteostasis.

  • Open Access

    Small molecule BLVRB redox inhibitor promotes megakaryocytopoiesis and stress thrombopoiesis in vivo

    by Natasha M. Nesbitt, Gian Luca Araldi, Lisa Pennacchia, Natalia Marchenko, Zahra Assar, Kendall M. Muzzarelli, Rahul Raghavan Thekke Veedu, Brian Medel-Lacruz, Eunjeong Lee, Elan Z. Eisenmesser, et al.

    Biliverdin IXβ reductase (BLVRB) is an NADPH-dependent enzyme previously implicated in a redox-regulated mechanism of thrombopoiesis distinct from the thrombopoietin (TPO)/c-MPL axis. Here, we apply computational modeling to inform molecule design, followed by de novo syntheses and screening of unique small molecules retaining the capacity for selective BLVRB inhibition as a novel platelet-enhancing strategy. Two distinct classes of molecules are identified, and NMR spectroscopy and co-crystallization studies confirm binding modes within the BLVRB active site and ring stacking between the nicotinamide moiety of the NADP+ cofactor. A diazabicyclo derivative displaying minimal off-target promiscuity and excellent bioavailability characteristics promotes megakaryocyte speciation in biphenotypic (erythro/megakaryocyte) cellular models and synergizes with TPO-dependent megakaryocyte formation in hematopoietic stem cells. Upon oral delivery into mice, this inhibitor expands platelet recovery in stress thrombopoietic models with no adverse effects. In this work, we identify and validate a cellular redox inhibitor retaining the potential to selectively promote megakaryocytopoiesis and enhance stress-associated platelet formation in vivo distinct from TPO receptor agonists.


  • Plakophilin3 loss leads to increased adenoma formation and rectal prolapse in APCmin mice

    by Rahul Raghavan, Navami Koyande, Rohit Beher, Neha Chetlangia, Mukda Ramadwar, Shital Pawade, Rahul Thorat, Jolanda van Hengel, Tetyana Sklyarova, Frans van Roy, et al.


  • Exploring the mechanisms of cytotoxic and anti-inflammatory property of andrographolide and its derivatives

    by Rahul Raghavan, Sanith Cheriyamundath, Joseph Madassery

    This review explores the mechanisms of cytotoxic and anti-inflammatory properties of andrographolide and derivatives of andrographolide in various cell lines. In vitro and in vivo studies that shed light on the molecular mechanisms of cytotoxicity and anti-inflammatory property of andrographolide and its derivatives are reviewed here. Cytotoxic effect of andrographolide on cancer cell lines are mainly due to the induction of reactive oxygen species, activation of c-Jun N-terminal kinase, inhibition of autophagy, and induction of apoptosis. Anti-inflammatory effect of andrographolide is predominantly due to the covalent inhibition of nuclear factor kappa B transcription factor and thereby inhibition of various targets genes such as tumor necrosis factor-alpha, interleukin-6, macrophage inflammatory protein-2, and nitric oxide synthase. Andrographolide is known to directly bind Ras protein; therefore, inhibition of growth factor-activated downstream pathways such as ERK1/2 pathway might be due to the direct inhibition of Ras functions. Inhibition of Ras pathway by antagonizing Ras protein might be a key event contributing to both cytotoxicity and anti-inflammatory functions of andrographolide. Evidence from literature study showed that derivatives of andrographolide such as neoandrographolide and 14-deoxy-11,12-didehydroandrographolides are potent anti-inflammatory agents with less cytotoxicity. Unfavorable chemical modifications such as sulfation and glucuronidation inside the body and fast removal from plasma are the major factors known to hinder the bioavailability of andrographolide.


  • Open Access

    EVALUATION OF IN VITRO ANTICANCER AND ANTIOXIDANT ACTIVITIES FROM LEAF EXTRACTS OF MEDICINAL PLANT CLIDEMIA HIRTA

    by Dokka Narasimham, Yeduguri Hima Bindu, Sanith Cheriyamundath, Rahul Raghavan, Meruva Keerthi Kumari, Thummala Chandrasekhar, Joseph Madassery

    Objective: To evaluate the anticancer and antioxidant activity of medicinal plant Clidemia hirta extracted in different solvents.Methods: Crude extracts were prepared from the leaves of Clidemia hirta using ethanol, petroleum ether and chloroform solvents. Anticancer activities and antioxidant properties were assayed using standard yellow dye 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and 1, 1-diphenyl-2-picryl hydrazyl (DPPH) free radical scavenging assay respectively.Results: We found that the ethanol extract had higher inhibition activities against Dalton’s lymphoma ascites (DLA) cancer cell line, 50% DLA cell line inhibition at 68µg/ml, while 50% inhibition by petroleum ether and chloroform extracts were at 160µg/ml and 172µg/ml, respectively. The antioxidant activity requires5µg/ml of ethanol extract to trap 50% of DPPH (IC50), whereas the positive control ascorbic acid trapped 50% of DPPH (IC50) at 3.5µg/ml.Conclusion: The prepared leaf extracts with different solvents of Clidemia hirta showed the antiproliferative and antioxidant activity in dose-dependent manner. Further works is required to identify the biologically active chemical constituents, responsible for cancer cell growth inhibition from this plant.


  • Open Access

    Dimethyl sulfoxide inactivates the anticancer effect of cisplatin against human myelogenous leukemia cell lines in in vitro assays

    by Joseph Madassery, Rahul Raghavan, Sanith Cheriyamundath

    Objectives: To investigate the effect of DMSO on cisplatin induced cytotoxicity (invitro) against K562 (Human mylogenous leukemia) cell line and to study the cisplatin-DMSO adduct formation using UV-spectrophotometer. Materials and methods: Effect of DMSO on the cytotoxicity of cisplatin was studied in K562 (Chronic mylogenous leukemia) cell line by MTT assay. Cisplatin-DMSO adduct formation was studied by continuously monitoring the increase in absorption peaks for 30 minutes using UV-spectrophotometer. Results: 0.1-0.3% DMSO markedly reduced the cytotoxic activity of cisplatin in K562 cells. Cisplatin-DMSO adduct formation was detected using UV-spectrophotometer. Continuous increase in UV absorbance between 250nm-290nm was observed when cisplatin (0.5mg/ml) and DMSO (10%) were mixed. Conclusion: Present study revealed that DMSO inactivates the cytotoxicity of cisplatin. Cisplatin-DMSO mixture showed increased absorbance at 250-290nm.Therefore, using DMSO in invitro assays might result in misinterpretation of actual efficacy of drugs.


  • Ethylidene-4,6-dimethoxycoumaran-3-one: the C2C8 double bond configuration

    by Karel D. Klika, Sanith Cheriyamundath, Rahul Raghavan, K.B. Megha, Asoke Banerji, Robert W. Owen, Joseph Madassery


  • 14-Deoxy-11,12-didehydroandrographolide inhibits proliferation and induces GSH-dependent cell death of human promonocytic leukemic cells

    by Rahul Raghavan, Sanith Cheriyamundath, Joseph Madassery

    14-Deoxy-11,12-didehydroandrographolide (AND2), an analogue of andrographolide, showed more potent cytotoxicity against human promonocytic leukemia (THP-1) cells than adherent cancer cell lines. In this study AND2 was isolated from the plant Andrographis paniculata and it was characterized. The antiproliferative effect of AND2 on both adherent (PC-3 and MDAMB) and non-adherent (THP-1 and Jurkat) cancer cell lines was evaluated by MTT assay. The effect of intracellular reduced glutathione (GSH) on AND2-induced cytotoxicity was studied by conducting cell viability assays on GSH-pretreated cells. The effect of AND2 on the redox status of THP-1 cells was determined by analyzing the endogenous reduced GSH content. Apoptosis induction was confirmed by DNA laddering assay and Western blot analysis using anti-caspase-3 protein antibody. AND2 showed antiproliferative action on both THP-1 and Jurkat cancer cell lines with low IC50 values. Cytotoxicity of AND2 was reversed by GSH pretreatment. AND2 treatment decreased the GSH content by 19.76 % (p Procaspase-3 expression reached a maximum in treated cells at 32 h and was markedly reduced at 48 h but no procaspase-3 cleavage was observed. The obtained results suggest that AND2 is more effective against leukemia cells. AND2 induced a redox-mediated cell death in THP-1 cells. As AND2 temporarily increased the procaspase-3 expression during treatment, this study encourages the preclinical testing of AND2 against promonocytic leukemia cells in combination with small molecules that directly activate procaspase-3 to caspase-3.